Masuda et al. commented that the systemic administration of SK-216, a PAI-1 specific inhibitor, reduced tumor angiogenesis, raising the possibility that systemic administration of a PAI-1 inhibitor could become a novel antiangiogenic therapy in the treatment of malignancies [37]. Here, SERPINE1 is linked to neoplasm.